REGN-7544
- Generic Name
- REGN-7544
A Study of REGN7544 for the Treatment in Adult Patients With Sepsis-Induced Hypotension
- First Posted Date
- 2024-09-23
- Last Posted Date
- 2025-05-13
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 76
- Registration Number
- NCT06608901
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇫🇷Hopital Cochin, Paris, Île-de-France, France
🇺🇸Emory University Hospital, Atlanta, Georgia, United States
Study of Natriuretic Peptide Receptor 1 (NPR1) Antagonist in Adult Patients With Postural Orthostatic Tachycardia Syndrome (POTS)
Phase 2
Recruiting
- Conditions
- Postural Orthostatic Tachycardia Syndrome (POTS)
- Interventions
- Drug: Placebo
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 81
- Registration Number
- NCT06593600
- Locations
- 🇺🇸
Mercy Gilbert Medical Center, Gilbert, Arizona, United States
🇺🇸North County Neurology Associates, Carlsbad, California, United States
🇺🇸Southern California Heart Specialists, Pasadena, California, United States
A Trial to Learn if Different Doses of REGN7544 Are Safe in Healthy Adult Participants
- First Posted Date
- 2023-08-01
- Last Posted Date
- 2024-08-12
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 80
- Registration Number
- NCT05970718
- Locations
- 🇳🇿
New Zealand Clinical Research, Christchurch, New Zealand
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath